Metrikler
Yayın
31
Açık Erişim
10
BM Sürdürülebilir Kalkınma Amaçları
Eğitim Bilgileri
2013 - Devam Ediyor
2013 - Devam EdiyorTıpta Uzmanlık
Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları, Türkiye
2006 - 2012
2006 - 2012Lisans
Marmara Üniversitesi, Tıp Fakültesi, Türkiye
Yabancı Diller
B2 Orta Üstü
B2 Orta Üstüİngilizce
A1 Başlangıç
A1 Başlangıçİtalyanca
Araştırma Alanları
Tıp
Sağlık Bilimleri
Dahili Tıp Bilimleri
İç Hastalıkları
Onkoloji
Akademik Faaliyetlere Dayalı Araştırma Alanları
Avesis Araştırma Alanları
WoS Araştırma Alanları
Scopus Araştırma Alanları
Makaleler
Tümü (25)
SCI-E, SSCI, AHCI (19)
SCI-E, SSCI, AHCI, ESCI (23)
ESCI (4)
Scopus (23)
TRDizin (4)
2025
20251. The lactate dehydrogenase-to-albumin ratio is a prognostic biomarker in extensive-stage small-cell lung cancer
YILMAZ F., Yaşar S., Tatar O. D., Yildirim H. c., Guven D. C., TABAN H., et al.
Acta Medica
, cilt.56, sa.3, ss.186-198, 2025 (TRDizin)
2024
20242. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma
Yildirim H. C., BAYRAM E., Chalabiyev E., Majidova N., Avci T., Guzel H. G., et al.
JOURNAL OF CHEMOTHERAPY
, 2024 (SCI-Expanded, Scopus)
2024
20243. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)
AKYILDIZ A., GÜVEN D. C., KÖKSAL B., KARAOĞLAN B. B., Kivrak D., Ismayilov R., et al.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
, cilt.281, sa.9, ss.4991-4999, 2024 (SCI-Expanded, Scopus)
2023
20234. Prognostic and predictive value of tumoral DNA damage repair protein expression in patients with resected pancreatic cancer
Ceylan F., Guven D. C., Taban H., Aktepe O., ŞAHİN T. K., Kilickap S., et al.
Clinics and Research in Hepatology and Gastroenterology
, cilt.47, sa.3, 2023 (SCI-Expanded, Scopus)
2022
20225. Prognosis of Liposarcoma Patients in Modern ERA: Single-Center Experience
DEMİR M., Guven D., AKTAŞ B. Y., GÜNER G., AKTEPE O. H., TABAN H., et al.
SOUTH ASIAN JOURNAL OF CANCER
, cilt.11, ss.287-292, 2022 (ESCI, Scopus)
2022
20226. Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease
YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.
JOURNAL OF CLINICAL MEDICINE
, cilt.11, sa.17, 2022 (SCI-Expanded, Scopus)
2022
20227. Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case Report
TABAN H., GÜVEN D. C., Kilickap S.
CUREUS JOURNAL OF MEDICAL SCIENCE
, cilt.14, sa.8, 2022 (ESCI)
2022
20228. Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better? Comment
Guven D. C., Taban H., Dizdar O.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.28, sa.1, ss.203-204, 2022 (SCI-Expanded, Scopus)
2022
20229. Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy
YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
, cilt.6, sa.1, ss.59-63, 2022 (ESCI, TRDizin)
2022
202210. Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy
YILDIRIM H. Ç., Güven D. C., Chalabiyev E., Taban H., YILMAZ F., YAŞAR S., et al.
Journal of Oncological Science
, cilt.8, sa.3, ss.143-147, 2022 (Scopus, TRDizin)
2022
202211. Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience
Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., TABAN H., et al.
FUTURE ONCOLOGY
, cilt.18, ss.323-331, 2022 (SCI-Expanded, Scopus)
2021
202112. Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database
Yekeduz E., Erturk I., Tural D., Karadurmus N., Karakaya S., Hizal M., et al.
FUTURE ONCOLOGY
, cilt.17, ss.4861-4869, 2021 (SCI-Expanded, Scopus)
2021
202113. Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-checkpoint inhibitors
GÜVEN D. C., AKTEPE O. H., TABAN H., AKTAŞ B. Y., GÜNER G., YILDIRIM H. H., et al.
BIOMARKERS IN MEDICINE
, cilt.15, sa.13, ss.1123-1130, 2021 (SCI-Expanded, Scopus)
2021
202114. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy
GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., et al.
SUPPORTIVE CARE IN CANCER
, cilt.29, sa.9, ss.5417-5423, 2021 (SCI-Expanded, Scopus)
2021
202115. PILE: a candidate prognostic score in cancer patients treated with immunotherapy
Guven D. C., Yildirim H. C., Bilgin E., Aktepe O. H., Taban H., Sahin T. K., et al.
CLINICAL & TRANSLATIONAL ONCOLOGY
, cilt.23, sa.8, ss.1630-1636, 2021 (SCI-Expanded, Scopus)
2021
202116. Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors
GÜVEN D. C., ŞAHİN T. K., AKSUN M. S., TABAN H., AKTEPE O. H., METİN AKSU N., et al.
SUPPORTIVE CARE IN CANCER
, cilt.29, sa.4, ss.2029-2035, 2021 (SCI-Expanded, Scopus)
2021
202117. Impact of albumin to globulin ratio on survival outcomes of patients with metastatic renal cell carcinoma
AKTEPE O. H., GÜNER G., GÜVEN D. C., TABAN H., YILDIRIM H. Ç., ŞAHİN T. K., et al.
TURKISH JOURNAL OF UROLOGY
, cilt.47, sa.2, ss.113-119, 2021 (ESCI, Scopus, TRDizin)
2021
202118. Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.
Yekeduz E., Erturk I., Tural D., Karadurmus N., Karakaya S., Hizal M., et al.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.39, sa.6, 2021 (SCI-Expanded, Scopus)
2021
202119. Adjuvant treatment with paclitaxel plus trastuzumab for node negative human epidermal growth factor receptor 2-positive breast cancer: Real life experience
Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., Olgun P., et al.
CANCER RESEARCH
, cilt.81, sa.4, 2021 (SCI-Expanded, Scopus)
2021
202120. What to expect from NCCN BRCA testing criteria: A retrospective cohort analysis
Aktas B. Y., Degirmenciler R. F., Durmaz C. D., Taban H., Guven D. C., Guner G., et al.
ANNALS OF ONCOLOGY
, cilt.32, 2021 (SCI-Expanded, Scopus)
2021
202121. Prognostic and predictive value of tumor-infiltrating lymphocytes in combination with systemic inflammatory markers in colon cancer
Efil S. C., Guner G., Guven D. C., Celikten B., Celebiyev E., Taban H., et al.
ANNALS OF ONCOLOGY
, cilt.32, 2021 (SCI-Expanded, Scopus)
2020
202022. Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)
HIZAL M., ŞENDUR M. A. N., YAŞAR H. A., Bir Yucel K., Arslan C., Ucar G., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.26, sa.7, ss.1583-1589, 2020 (SCI-Expanded, Scopus)
2020
202023. Defining the Optimal Regimen for Stage III Colon Cancer: Concerns with Study Design
GÜVEN D. C., GÜNER G., AKTAŞ B. Y., AKTEPE O. H., TABAN H., ARIK Z.
CLINICAL COLORECTAL CANCER
, cilt.19, sa.3, 2020 (SCI-Expanded, Scopus)
2020
202024. The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer
YAŞAR H. A., Yucel K. B., Arslan C., Ucar G., Karakaya S., Bilgin B., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.26, sa.5, ss.1110-1116, 2020 (SCI-Expanded, Scopus)
2020
202025. Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer
GÜVEN D. C., KILIÇKAP S., GÜNER G., TABAN H., DİZDAR Ö.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.26, sa.1, ss.256-258, 2020 (SCI-Expanded, Scopus)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
2024
20241. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: A retrospective multi-center study by the Turkish Oncology Group (TOG).
Akyildiz A., Guven D. C., Koksal B., Karaoglan B. B., Salim D. K., Sutcuoglu O., et al.
Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, (Özet Bildiri)
2020
20202. Prognostic role of tumoral DNA damage repair protein expression in patients with resectable pancreatic cancer
Ceylan F., Guven D. C., Taban H., Aktepe O., Kilickap S., Turker A., et al.
ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31, (Özet Bildiri)
2020
20203. Daily chemotherapy and treatment unit in the COVID-19 era: Lessons of the first 60 days
Aktas B. Y., Guven D. C., Degirmenciler R. F., Taban H., Aktepe O. H., Kertmen N., et al.
ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31, (Özet Bildiri)
2019
20194. Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe experience
AKSOY S., DEĞİRMENCİLER R. F., AKTAŞ B. Y., Guven D. C., AKTEPE O. H., Guner G., et al.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, (Özet Bildiri)
2019
20195. Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology Hospital
Guven D. C., AKTEPE O. H., Berk Z., Guner G., Taban H., AKTAŞ B. Y., et al.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, (Özet Bildiri)
2019
20196. Clinical features and prognosis of patients with liposarcoma: Single-center experience.
Demir M., Guven D. C., Aktas B. Y., Guner G., Aktepe O. H., Taban H., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri)